Hematopoietic stem cell transplantation in an adult patient with primary hemophagocytic lymphohistiocytosis
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e347Keywords:
Cytokine Release Syndrome, Hematopoietic Stem Cell Transplantation, Lymphohistiocytosis, HemophagocyticAbstract
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory condition characterized by uncontrolled immune activation and excessive production of pro-inflammatory cytokines, which may rapidly progress to multiorgan failure. Despite efforts to simplify the diagnosis and treatment of this entity, it remains a major challenge in clinical practice, especially in adults. We report a case of suspected primary HLH in an adult patient with a prolonged history of recurrent inflammatory episodes and a fulminant presentation requiring intensive care support. Despite the absence of identifiable genetic mutations, the clinical course was highly suggestive of an underlying primary immune dysregulation. The patient achieved remission with HLH-2004–based therapy and subsequently underwent haploidentical hematopoietic stem cell transplantation (HSCT) due to high risk of recurrence. Seven months after transplantation, she remains in complete remission with full donor chimerism and only mild chronic graft-versus-host disease. This case highlights the diagnostic complexity of adult HLH, the limitations of genetic testing, and supports early consideration of HSCT in selected high-risk patients.
References
1. Gioia C, Paroli M, Izzo R, Di Sanzo L, Rossi E, Pignatelli P, Accapezatto D. Pathogenesis of hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a case report and review of the literature. Int J Mol Sci. 2024;25(11):5921. https://doi.org/10.3390/ijms25115921
2. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-16. https://doi.org/10.1016/S0140-6736(13)61048-X
3. Henter JI, Horne AC, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31. https://doi.org/10.1002/pbc.21039
4. Astigarraga I, González-Granado LI, Allende LM, Alsina L. Haemophagocytic syndromes: the importance of early diagnosis and treatment. An Pediatr (Barc). 2018;89(2):124.e1-e8. https://doi.org/10.1016/j.anpedi.2018.05.003
5. La Rosée P, Horne AC, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-77. https://doi.org/10.1182/blood.2018894618
6. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373-74.
7. Li J, Wang Q, Zheng W, Ma J, Zhang W, Wang W, Tian X. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine. 2014;93(2):100-5. https://doi.org/10.1097/MD.0000000000000022
8. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-20. https://doi.org/10.1002/art.38690
9. Caicedo-Herrera G, Candelo E, Olaya M, Pérez P, Medina D, Pachajoa H. Trasplante de médula óssea exitoso en un caso de linfohistiocitosis hemofagocítica familiar tipo 3. Andes Pediatr. 2021;92(2):269-73. https://doi.org/10.32641/andespediatr.v92i2.2696
10. Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, for the BMT CTN 1703 Investigators. Post-transplantation cyclophosphamide-based graft-versushost disease prophylaxis. N Engl J Med. 2023;388(25):2338-48. https://doi.org/10.1056/NEJMoa2215943
11. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RFD, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers MED. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001
12. Jumic S, Nand S. Hemophagocytic lymphohistiocytosis in adults: associated diagnoses and outcomes, a ten-year experience at a single institution. J Hematol. 2019;8(4):149-54. https://doi.org/10.14740/jh592
13. Arcuri MT, Valle VA. Linfohistiocitose hemofagocítica em adultos [Internet]. Rio de Janeiro: Instituto Nacional de Câncer José Alencar Gomes da Silva; 2017 [cited 2025 Dec 11]. Available from: https://ninho.inca.gov.br/jspui/handle/123456789/10172
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sthephanie de Lima Zielak, Simone Cunha Maradei, Tiago de Oliveira Boechat
This work is licensed under a Creative Commons Attribution 4.0 International License.
